General Payment Systems, Inc.

Lake Forest, CA · Biotech · Still private

Oral GLP-1 peptide therapeutics and portable bioreactor platform for peptide manufacturing

Claim this profile

Follows are private to you and power your alerts

Updated · general.bio

Sector
Biotech
Headquarters
Lake Forest, CA
Latest Form D
$10K, Jun 2016
Total capital
$6.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$6.8M
10 Form D · last Jun 2016
125 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201120122013201420152016FEDERAL ↑EQUITY ↓Cumulative $6.8M1st Form D$464K3rd Form D$3M8th Form D$1.8M
201120122013201420152016FEDERAL ↑EQUITY ↓Cumulative $6.8M3rd Form D$3M8th Form D$1.8M

Latest events

  • Private capital raisedForm D · SEC · 10th filing$10K
  • Private capital raisedForm D · SEC · 9th filing$13K
  • Private capital raisedForm D · SEC · 8th filing$1.8M
  • Private capital raisedForm D · SEC · 7th filing$673K
  • Private capital raisedForm D · SEC · 6th filing$307K
  • Private capital raisedForm D · SEC · 5th filing$24K
  • Private capital raisedForm D · SEC · 4th filing$400K
  • Private capital raisedForm D · SEC · 3rd filing$3M
  • Private capital raisedForm D · SEC · 2nd filing$60K
  • Private capital raisedForm D · SEC · 1st filing$464K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing in Biotech · 4373 companies

Line = median
  • Federal contractsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Gregg HodgePromoterNamed in SEC Form D filings
  • James SylvesterExecutive Officer, DirectorNamed in SEC Form D filings
  • Paul TalbotDirectorNamed in SEC Form D filings
  • Ronald HodgeExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Vinay PatelDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Tradewind BioScienceSimilar federal contract value in Biotech · null in contracts
  • Ampersand BiomedicinesSimilar federal contract value in Biotech · null in contracts
  • EXBAQ LLCSimilar federal contract value in Biotech · null in contracts
  • Carogen CorporationSimilar federal contract value in Biotech · null in contracts
  • ALKEUS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
  • IMMUNIC, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .